The authoritative expert who chaired the DSM-IV revision has become a formidable critic whose publicly expressed views about psychiatry’s diagnostic assessments and prescribed treatments–mostly chemical interventions–validate the criticism expressed by the Alliance for Human Research Protection for more than a dozen years. Continue reading →
"Our systems of mental health care have become too medication focused, and it’s time for a broader approach. History will show that this national shift began this weekend in Portland, Oregon.” Continue reading →
*More antipsychotic treatment was associated with smaller gray matter volumes. Progressive decrement in white matter volume was most evident among patients who received more antipsychotic treatment. Continue reading →
New FDA antipsychotic Warnings: "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding." Continue reading →
"This case goes beyond everything and anything, and this should have brought the house down on the university." Continue reading →
Panel Chairman Thomas G. Brott, a neurologist at the Mayo Clinic, said he was amazed that essentially no research had been done on ECT’s effects using functional MRI imaging, repeated brain wave (EEG) studies, or autopsy examinations of patients. Continue reading →
At the end of today’s hearings, an FDA advisory panel will issue recommendations about whether manufacturers of electroconvulsive devices must put their devices to rigorous safety tests or whether they should be reclassified from Class III (high risk) to Class II (moderate . . . Continue reading →
"Despite ongoing controversy, there has never been a large-scale, prospective study of the cognitive effects of electroconvulsive therapy (ECT)." Dr. Harold Sackeim, et al, 2007.
The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis. However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken . . . Continue reading →
Why the tragic case of Dna Markingson and the culpability of the University of Minnesota won’t go away… Continue reading →
In 2008, 6,485 trials were conducted off shore with almost no FDA oversight. Seventy-eight percent of all human test subjects were enrolled at foreign sites.